- Home
- GNW vs ARQT Comparison
GNW vs ARQT Comparison
Compare GNW & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | ARQT |
|---|---|---|
| Founded | 1871 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.5B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GNW | ARQT |
|---|---|---|
| Price | $10.10 | $27.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.50 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $7,301,000,000.00 | $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | N/A | $29.39 |
| P/E Ratio | $83.96 | ★ N/A |
| Revenue Growth | 0.08 | ★ 91.34 |
| 52 Week Low | $7.32 | $13.70 |
| 52 Week High | $10.15 | $31.77 |
Technical Indicators
Market Signals| Indicator | GNW | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 74.74 | 58.86 |
| Support Level | $8.01 | $27.63 |
| Resistance Level | N/A | $29.91 |
| Average True Range (ATR) | 0.21 | 1.23 |
| MACD | 0.06 | -0.08 |
| Stochastic Oscillator | 95.52 | 54.47 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.